Scholars Central

Short communicationPublished 12 Dec 2019

Targeting chronic myeloid leukemia stem cells

Authors: Shaoguang Li

Stem Cell Research and Regenerative Medicine

Volume 2 · Issue 2 · Pages 01

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cancer stem cells in many hematologic malignancies and some solid tumors are associated with cancer initiation and insensitivity to chemotherapy and need to be eradicated for achieving a cure. A successful cancer therapy relies on targeting critical signaling genes that play a key role in the maintenance of cancer stem cell survive and proliferation. Hence, it will be vital to fully apprehend the molecular mechanisms by which cancer stem cells survival and proliferate. Toward this goal, a physiological cancer stem cell disease model is required for identifying and testing genes/pathways that play an essential role in functional regulation of cancer stem cells and can be targeted for eradicating these stem cells. Human continual myeloid leukemia (CML) triggered by way of the BCR-ABL oncogene is derived from a stem cell, serving as a good disease model for studying the molecular biology of cancer stem cells. In CML, BCR-ABL tyrosine kinase inhibitors including imatinib mesylate (Gleevec) are fairly effective in controlling continual section CML, but they fail to eliminate leukemia-starting up cells or leukemia stem cells (LSCs) in CML mice and patients. Clinically, an entire and sustained molecular remission (undetectable stages of BCR-ABL transcripts) is difficult to gain even after an entire cytogenetic remission achieved thru imatinib treatment. It has emerge as clean that BCR-ABL kinase inhibitors can efficiently kill exceptionally proliferating leukemia cells but are incapable of eradicating LSCs for cure. An anti-LSC strategy needs to be developed. Our laboratory has been focusing on know-how the biology of LSCs in CML to identify key genes that modify survival and proliferation of LSCs, assisting us to expand new therapeutic techniques via targeting LSCs.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Stem Cell Research and Regenerative Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalStem Cell Research and Regenerative Medicine
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Shaoguang Li”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels